InflaRx N.V. (NASDAQ:IFRX) Sees Large Decline in Short Interest

Key Points

• InflaRx N.V. experienced a significant 50.1% decrease in short interest, dropping from 908,600 shares to 453,200 shares as of August 31st.
• Analysts have set new price targets for InflaRx, with Oppenheimer lowering their target from $6.00 to $3.00, while HC Wainwright set a target of $6.00, reflecting a consensus rating of "Buy".
• The company has a market cap of $84.59 million and reported a quarterly revenue of $0.05 million, meeting analysts' expectations.

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 453,200 shares, a decrease of 50.1% from the August 15th total of 908,600 shares. Based on an average trading volume of 491,400 shares, the short-interest ratio is currently 0.9 days. Approximately 0.8% of the shares of the stock are sold short. Approximately 0.8% of the shares of the stock are sold short. Based on an average trading volume of 491,400 shares, the short-interest ratio is currently 0.9 days.

Analysts Set New Price Targets

A number of research analysts recently weighed in on IFRX shares. Oppenheimer dropped their price objective on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Raymond James Financial lowered InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price objective on the stock. in a research note on Thursday, May 29th. Finally, HC Wainwright assumed coverage on InflaRx in a research note on Tuesday, September 2nd. They set a "buy" rating and a $6.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $6.20.

InflaRx Price Performance

InflaRx stock opened at $1.26 on Friday. The stock's 50-day moving average is $1.03 and its 200-day moving average is $1.13. The company has a market cap of $84.59 million, a price-to-earnings ratio of -1.57 and a beta of 1.43. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million. Research analysts anticipate that InflaRx will post -1.04 EPS for the current year.

Institutional Investors Weigh In On InflaRx

A number of large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new stake in InflaRx during the 4th quarter valued at approximately $55,000. XTX Topco Ltd acquired a new stake in InflaRx during the 1st quarter valued at approximately $38,000. Concurrent Investment Advisors LLC acquired a new stake in InflaRx during the 2nd quarter valued at approximately $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock valued at $118,000 after purchasing an additional 91,927 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx during the 2nd quarter valued at approximately $262,000. Institutional investors and hedge funds own 42.39% of the company's stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.